These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 24058182)

  • 1. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.
    Makki N; Swaminathan PD; Hanmer J; Olshansky B
    Europace; 2014 Jan; 16(1):55-62. PubMed ID: 24058182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death.
    Cuculich PS; Sánchez JM; Kerzner R; Greenberg SL; Sengupta J; Chen J; Faddis MN; Gleva MJ; Smith TW; Lindsay BD
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):207-13. PubMed ID: 17338717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.
    Bansal N; Szpiro A; Reynolds K; Smith DH; Magid DJ; Gurwitz JH; Masoudi F; Greenlee RT; Tabada GH; Sung SH; Dighe A; Go AS
    JAMA Intern Med; 2018 Mar; 178(3):390-398. PubMed ID: 29404570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with chronic kidney disease and implantable cardiac defibrillator: primary versus secondary prevention.
    Hage FG; Aljaroudi W; Aggarwal H; Bhatia V; Miller J; Doppalapudi H; Wazni O; Iskandrian AE
    Int J Cardiol; 2013 Apr; 165(1):113-6. PubMed ID: 21862150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
    Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
    J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?
    Fu L; Zhou Q; Zhu W; Lin H; Ding Y; Shen Y; Hu J; Hong K
    Int Heart J; 2017 May; 58(3):371-377. PubMed ID: 28539571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis.
    Korantzopoulos P; Liu T; Li L; Goudevenos JA; Li G
    Europace; 2009 Nov; 11(11):1469-75. PubMed ID: 19812050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
    Charytan DM; Patrick AR; Liu J; Setoguchi S; Herzog CA; Brookhart MA; Winkelmayer WC
    Am J Kidney Dis; 2011 Sep; 58(3):409-17. PubMed ID: 21664735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community.
    Narayanan K; Reinier K; Uy-Evanado A; Teodorescu C; Chugh H; Marijon E; Gunson K; Jui J; Chugh SS
    Circulation; 2013 Oct; 128(16):1733-8. PubMed ID: 24048201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.
    Bansal N; Szpiro A; Masoudi F; Greenlee RT; Smith DH; Magid DJ; Gurwitz JH; Reynolds K; Tabada GH; Sung SH; Dighe A; Cassidy-Bushrow A; Garcia-Montilla R; Hammill S; Hayes J; Kadish A; Sharma P; Varosy P; Vidaillet H; Go AS
    Heart; 2017 Apr; 103(7):529-537. PubMed ID: 27742796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of death in chronic kidney disease: the role of implantable cardioverter defibrillators.
    Turner S; Onalan O; Bickle B
    CANNT J; 2009; 19(3):29-36; quiz 37-8. PubMed ID: 19899497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.
    Williams ES; Shah SH; Piccini JP; Sun AY; Koontz JI; Al-Khatib SM; Hranitzky PM
    Europace; 2011 Dec; 13(12):1717-22. PubMed ID: 21821855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
    Peck KY; Lim YZ; Hopper I; Krum H
    Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
    Pun PH; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Hallstrom A; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Hess PL; Inoue LY; Sanders GD
    Am J Kidney Dis; 2014 Jul; 64(1):32-9. PubMed ID: 24518128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.